Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer
Condition(s):Breast CancerLast Updated:February 28, 2020Unknown status
Hide Studies Not Open or Pending
Condition(s):Breast CancerLast Updated:February 28, 2020Unknown status
Condition(s):Breast CancerLast Updated:October 25, 2022Completed
Condition(s):Triple Negative Breast Cancer; Locally Advanced Breast Cancer; Recurrent Breast Cancer; Metastatic Breast Cancer; ER+ Breast Cancer; HER2-positive Breast CancerLast Updated:January 9, 2023Recruiting
Condition(s):COVID-19Last Updated:November 7, 2022Withdrawn
Condition(s):Cancer, AdvancedLast Updated:June 21, 2018Withdrawn
Condition(s):Advanced Breast Cancer FemaleLast Updated:January 20, 2022Completed
Condition(s):Pancreatic Neuroendocrine CancerLast Updated:January 23, 2018Completed
Condition(s):Breast Cancer FemaleLast Updated:June 29, 2022Completed
Condition(s):Breast CancerLast Updated:March 23, 2022Active, not recruiting
Condition(s):Ovarian CancerLast Updated:February 11, 2022Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.